Manage Edit Post Logout Login

Halister News

Halister Partners

« Back to blog

HALISTER: Pfizer Sees FY16 Rev. $52.0B-$53.0B, Saw $51B-$53B

Pfizer Sees FY16 Rev. $52.0B-$53.0B, Saw $51B-$53B

(Bloomberg) -- Pfizer 3Q adj EPS 61c, est. 62c.
  • NOTE: Earlier, Pfizer Stops Development of PCSK9 Bococizumab, Sees 4C Charge Link
Statement:Link
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
PFE US (Pfizer Inc)

To de-activate this alert, click here

UUID: 7947283
Download x-rimdevice-bloomberg-news-nlrt.blp
Upvote Upvoted 0
Tweet
Like this post?
Subscribe by email » We'll email you when there are new posts here.
You're following this blog. Unfollow »
Follow this Posthaven »
Enter your email address to get email alerts about new posts on this site. Unsubscribe anytime.
Email address is invalid.

Posted